Evidence map›Paper›PMID 36713585›Full record

ArticleFrontiers in oncology2022

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report.

Matteo Allegretti, Vittoria Barberi, Cristiana Ercolani, Antonello Vidiri, Elena Giordani, Gennaro Ciliberto, Patrizio Giacomini, Alessandra Fabi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Matteo AllegrettiTranslational Oncology Research, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Vittoria BarberiMedical Oncology 1, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Cristiana ErcolaniPathology, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Antonello VidiriRadiology and Diagnostic Imaging, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Elena GiordaniTranslational Oncology Research, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Gennaro CilibertoScientific Directorate, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Patrizio GiacominiClinical Trial Center, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Alessandra FabiPrecision Medicine in Senology, Scientific Directorate - Department of Women and Child Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Agostino Gemelli University Polyclinic · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Under therapeutic pressure aggressive tumors evolve rapidly. Herein, a luminal B/HER2-low breast cancer was tracked for >3 years during a total of 6 largely unsuccessful therapy lines, from adjuvant to advanced settings. Targeted next generation sequencing (NGS) of the primary lesion, two metastases and 14 blood drawings suggested a striking, unprecedented coexistence of three evolution modes: punctuated, branched and convergent. Punctuated evolution of the trunk was supported by

Indexed as

breast cancercancer evolutionESR1HER2liquid biopsymolecular tumor board

Identifiers

PMID36713585
PMCPMC9874630
OpenAlexW4315497891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.